Bisaro Paul 4

What Happened

• Paul Bisaro, a director of Myriad Genetics (MYGN), received a grant of 59,701 restricted stock units (RSUs) on 2026-06-04. The Form 4 reports an acquisition at $0.00 per unit (code A — award/grant), reflecting a compensation award rather than a purchase of stock.
• These RSUs represent a contingent right to receive one share of common stock per unit when they vest; the filing reports no immediate cash value or sale.

Key Details

• Transaction date: 2026-06-04; Filing date (accession): 2026-06-05 — filed promptly.
• Transaction type/code: Award/Grant (A).
• Units granted: 59,701 RSUs; reported price: $0.00; reported total value on Form 4: $0.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: RSUs granted under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan. Each RSU vests on the earlier of (a) the first anniversary of the grant or (b) the date of the next annual meeting of stockholders following the grant.

Context

• RSU grants are common compensation for directors and do not represent an immediate cash investment or sale. They convert to shares only upon vesting, so they are not an immediate bullish trade signal.
• No indication of a 10b5-1 trading plan, cashless exercise, gift, or tax-withholding sale in this filing.